Thursday, July 26, 2018 4:05:45 PM
DERM 30% Returns from $10.00
Patience folks.
Patience folks.
I am not an Investment Advisor/Broker and you should do your own research before you buy/sell any stock.
Recent DERM News
- Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference • GlobeNewswire Inc. • 05/19/2026 08:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:33:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:06:07 PM
- Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 05/13/2026 08:01:00 PM
- Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 • GlobeNewswire Inc. • 05/06/2026 08:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 08:09:51 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:06:04 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:03:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 09:29:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 09:27:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 09:20:21 PM
- Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™ • GlobeNewswire Inc. • 04/21/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:05:13 PM
- Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/25/2026 08:01:00 PM
- Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/23/2026 09:06:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/23/2026 09:05:23 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/15/2026 09:43:58 PM
- Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology • GlobeNewswire Inc. • 12/10/2025 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 09:41:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 09:07:15 PM
- Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 11/12/2025 09:01:00 PM
- Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 • GlobeNewswire Inc. • 11/05/2025 01:30:00 PM
- Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference • GlobeNewswire Inc. • 10/24/2025 12:30:18 PM
